An interventional study of Creatine Monohydrate and Omega 3 FA (Fish Oil) in Delayed Onset Muscle Soreness, Exercise-induced Muscle Damage and Muscle Recovery, sponsored by Antonio Molina Lopez. Completed at 1 site in Spain. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Antonio Molina Lopez · Not applicable, Interventional, and Basic science
This randomized, placebo-controlled, parallel-group trial investigated the effects of combined antioxidant and anti-inflammatory supplementation on delayed onset muscle soreness (DOMS) recovery in trained women. Sixty trained women (18-35 years) were randomized into four groups: G1 (Creatine + Omega-3), G2 (Creatine + Omega-3 + NAC), G3 (Creatine + Omega-3 + NAC + CoQ10), and G4 (Placebo). Outcomes included muscle pain pressure threshold, countermovement jump, handgrip strength, 30-meter sprint, bilateral dynamometry, infrared thermography, creatine kinase, and heart rate variability, assessed before and after an eccentric exercise protocol.
Delayed onset muscle soreness (DOMS) is a common physiological response to eccentric exercise, characterized by muscle pain, reduced force production, and impaired neuromuscular function. Antioxidant and anti-inflammatory compounds such as creatine, omega-3 fatty acids, N-acetylcysteine (NAC), and coenzyme Q10 (CoQ10) have been proposed as potential modulators of exercise-induced muscle damage. This study used a 4-arm parallel RCT design with participant and assessor blinding. Participants underwent a standardized eccentric exercise protocol to induce DOMS, followed by 72 hours of monitoring. Measurements were taken at baseline (T1), post-exercise (T2), 24h (T3), 48h (T4), and 72h (T5) post-exercise. Analysis of covariance (ANCOVA) was performed with baseline values and age as covariates.
Antonio Molina Lopez is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received creatine monohydrate (5 g/day) combined with omega-3 fish oil (2 capsules/day; 456 mg EPA + 225 mg DHA per capsule) for 4 weeks. The final week coincided with the 5 assessment timepoints following the eccentric exercise protocol to induce DOMS.
Dietary Supplement: Creatine Monohydrate · Dietary Supplement: Omega 3 FA (Fish Oil)
Participants received creatine monohydrate (5 g/day), omega-3 fish oil (2 capsules/day; 456 mg EPA + 225 mg DHA), N-acetylcysteine (600 mg/day) for 4 weeks. The final week coincided with the 5 assessment timepoints following the eccentric exercise protocol to induce DOMS.
Dietary Supplement: Creatine Monohydrate · Dietary Supplement: Omega 3 FA (Fish Oil) · Dietary Supplement: N-Acetyl Cysteine (NAC)
Participants received creatine monohydrate (5 g/day), omega-3 fish oil (2 capsules/day; 456 mg EPA + 225 mg DHA), N-acetylcysteine (600 mg/day), and coenzyme Q10 (100 mg/day) for 4 weeks. The final week coincided with the 5 assessment timepoints following the eccentric exercise protocol to induce DOMS.
Dietary Supplement: Creatine Monohydrate · Dietary Supplement: Omega 3 FA (Fish Oil) · Dietary Supplement: N-Acetyl Cysteine (NAC) · Dietary Supplement: Coenzyme Q10 100 MG Oral Capsule
Participants received a placebo consisting of maltodextrin (5 g/day) and olive oil capsules (2 capsules/day), visually identical to the active arms in capsule size, sachet format, and packaging colour, for 4 weeks.
Dietary Supplement: Placebo
Creatine monohydrate administered at 5 g/day for 4 weeks. Used in G1, G2, and G3 arms
Administered as 2 capsules/day (456 mg EPA + 225 mg DHA per capsule; EPA:DHA ratio 2:1) for 4 weeks. Included in G1, G2, and G3 arms.
Administered at 600 mg/day for 4 weeks. Included in G2 and G3 arms.
Administered at 100 mg/day for 4 weeks. Included in G3 arm only.
Maltodextrin (5 g/day) and olive oil capsules (2 capsules/day), visually identical to active arms. Administered for 4 weeks in G4 arm.
Countermovement Jump Height (CMJ)
Assessed using My Jump Lab app (240 fps). Jump height in centimeters as indicator of lower limb neuromuscular performance recovery
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
Muscle Pain Pressure Threshold
Assessed using a pressure algometer (BASELINE). Measures the minimum pressure at which the participant perceives pain, expressed in kg/cm²
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
30- Meter Sprint Time
Assessed using Witty photocell system (Microgate). Time in seconds to complete a 30-meter sprint.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
Creatine Kinase (CK)
ssessed using SimplexTAS 101 analyzer. Serum CK activity in U/L as a biochemical marker of muscle damage.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
RIGHT LEG DYNAMOMENTRY
Assessed using Activforce 2 dynamometer. Maximum isometric knee extension force in kg.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
LEFT LEG DYNAMOMETRY
Assessed using Activforce 2 dynamometer. Maximum isometric knee extension force in kg.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
Thermography
Assessed using FLIR T2 A315 thermographic camera. Skin temperature of the quadriceps region in degrees Celsius as marker of local inflammation.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
Heart Rate Variability
Assessed using Polar Team Pro chest straps. 5-minute supine recording with eyes closed and deep breathing. Root mean square of successive differences in ms as autonomic recovery indicator.
Time frame: Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5)
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in the published article, after de-identification, will be made available upon reasonable request to the corresponding author. Data will include all outcome variables assessed at each time point (T1-T5) for all 60 participants. Requests should be directed to the corresponding author and will be considered on a case-by-case basis following publication.
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Apr 2026, 2 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Creatine monohydrate · Fish Oils · Acetylcysteine · Coenzyme Q10
Antonio Molina Lopez